News

A test-and-treat strategy was effective at identifying and treating hepatitis C among migrants and refugees in Italy coming from low-income countries where the condition…

Treatment with Ocaliva (obeticholic acid) — an oral therapy with conditional approval in both the U.S. and Europe — reduced levels of additional markers…

Up to two years of daily treatment with Livmarli (maralixibat) controlled itch and reduced blood levels of bile acids and bilirubin, two markers of…

Children with biliary atresia who have a serious condition called acute-on-chronic liver failure (ACLF) tend to require a longer stay in the hospital and are…

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to larsucosterol, Durect’s investigational therapy for people with severe alcohol-associated hepatitis…

One year of treatment with Gilead Sciences’ seladelpar normalized biomarkers of liver injury and rapidly reduced itch for most people with primary biliary…

Two scores calculated from blood biomarkers can accurately discriminate between pregnant women with intrahepatic cholestasis of pregnancy (ICP) and those without, and predict ICP-associated…

Can-Fite BioPharma has been approved to enroll U.S. patients in its ongoing Phase 2b clinical trial of the oral treatment candidate namodenoson in people…

A toddler boy with cirrhosis, or permanent liver scarring, due to Alagille syndrome developed a hepatoblastoma, a type of liver cancer that typically occurs…

A Phase 2a clinical trial testing Kezar Life Sciences’ investigational therapy zetomipzomib in adults with autoimmune hepatitis who did not respond well to standard…